Kengreal, Kengrexal (cangrelor) is a small molecule pharmaceutical. Cangrelor was first approved as Kengreal on 2015-03-23. It has been approved in Europe to treat acute coronary syndrome and vascular surgical procedures. The pharmaceutical is active against P2Y purinoceptor 12. In addition, it is known to target uracil nucleotide/cysteinyl leukotriene receptor and P2Y purinoceptor 13. Kengreal's patents are valid until 2035-07-10 (FDA).
|Indication||acute coronary syndrome, vascular surgical procedures|
|Drug Class||Platelet aggregation inhibitors|